Pharmidex partners in European Commission H2020 award
May 21, 2017

Pharmidex joins Horizon 2020 EU project to work on radioactive contamination

Pharmidex partners in European Commission H2020 award

This project aims to stimulate intersectoral and international collaboration within Europe and with an ICPC country, Kazakhstan, in the area of novel nanoporous and nanostructured adsorbents for the treatment of very serious health conditions associated with acute and chronic exposure to external radiation and uptake of heavy metals and radiation as a consequence of accidental, occupational or deliberate activities and events.


This can dramatically lower the quality of life of the people affected and at present the treatment available is costly and inefficient. Radioactive contamination is a particularly serious problem in two of the countries participating in this project, namely, Ukraine and Kazakhstan, on large territories of the Chernobyl zone and around Semipalatinsk nuclear test site, respectively.


A large number of people are affected by living in the areas with elevated level of radioactivity with uncertain long-term consequences to their health and the health of future generations.


The expected impact of the project results is development of efficient and cost-effective methods of protection of first responders, population and cancer patients treated with radiotherapy from elevated doses of external and incorporated radiation and for occupational health protection of personnel working and the population living in areas contaminated with heavy metals.


Please find more information on the following web page: http://cordis.europa.eu/project/rcn/207057_en.html

February 4, 2026
At Pharmidex , we deliver high-quality LC-MS bioanalysis to support drug development across a wide range of analysis. Our experienced team supports preclinical, translational and clinical studies, providing accurate, reliable data under GLP and GCP to help drive confident decision-making. Learn more about our LC-MS capabilities: https://www.pharmidex.com/Discovery-Bioanalysis
February 2, 2026
Pharmidex offers high-quality Clinical Chemistry services delivering accurate, reliable data to support drug development. Our expert team and robust, quality-driven workflows enable trusted results that help accelerate decision-making and strengthen collaboration with pharma companies, CROs and academic partners. By working together, we support better science and more efficient drug development. 👉 Learn more: https://www.pharmidex.com/Clinical-chemistry
January 29, 2026
Pharmidex is delighted to share that Ash Alavijeh , Head of Operations, will be attending the UK BioIndustry Association (BIA) Annual Gala Dinner at the Roundhouse, London. Ash is looking forward to connecting with pharma and biotech colleagues to explore new collaborations, partnerships, and opportunities, all with the shared goal of advancing drug discovery and development. If you’re attending, feel free to connect with Ash this evening.
More Posts